Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Hennessy

Showing results (131-140 of 249) with videos related to

Pageof 25
Sort By:
Oncogene|February 12, 2020
Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancerSean P Kennedy, Michael O'Neill, Darren Cunningham, et al.
Diabetes Care|February 14, 2025
The Glycemic Impact of Protein Ingestion in People With Type 1 DiabetesGiang M Dao, Greg M Kowalski, Clinton R Bruce, et al.
Cancers|May 14, 2022
The SARS-CoV-2 Pandemic and Cancer Trials Ireland: Impact, Resolution and LegacySeamus O'Reilly, Verena Murphy, Eibhlin Mulroe, et al.
Advances in Experimental Medicine and Biology|May 24, 2008
Ovarian cancer: linking genomics to new target discovery and molecular markers--the way aheadBryan T Hennessy, Mandi Murph, Meera Nanjundan, et al.
Scientific Reports|May 26, 2026
Whole genome sequencing of pre-treatment and post-treatment locally advanced rectal cancer using long and short read technologiesLauren McAuley, Lydia O'Sullivan, Liam Grogan, et al.
Therapeutic Advances in Medical Oncology|February 1, 2018
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancersMalgorzata Milewska, Mattia Cremona, Clare Morgan, et al.
Blood|March 26, 2009
Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approachMatthias Niedermeier, Bryan T Hennessy, Zachary A Knight, et al.
Investigational New Drugs|April 23, 2020
Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd ALaura Breen, Patricia B Gaule, Alexandra Canonici, et al.
Cancer Cell|April 7, 2009
Rak functions as a tumor suppressor by regulating PTEN protein stability and functionEun-Kyoung Yim, Guang Peng, Hui Dai, et al.
The Journal of Clinical Investigation|June 10, 2010
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancerTodd W Miller, Bryan T Hennessy, Ana M González-Angulo, et al.
Pageof 25

Showing results (131-140 of 249) with videos related to

Sort By:
Pageof 25
Oncogene|February 12, 2020
Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancerSean P Kennedy, Michael O'Neill, Darren Cunningham, et al.
Diabetes Care|February 14, 2025
The Glycemic Impact of Protein Ingestion in People With Type 1 DiabetesGiang M Dao, Greg M Kowalski, Clinton R Bruce, et al.
Cancers|May 14, 2022
The SARS-CoV-2 Pandemic and Cancer Trials Ireland: Impact, Resolution and LegacySeamus O'Reilly, Verena Murphy, Eibhlin Mulroe, et al.
Advances in Experimental Medicine and Biology|May 24, 2008
Ovarian cancer: linking genomics to new target discovery and molecular markers--the way aheadBryan T Hennessy, Mandi Murph, Meera Nanjundan, et al.
Scientific Reports|May 26, 2026
Whole genome sequencing of pre-treatment and post-treatment locally advanced rectal cancer using long and short read technologiesLauren McAuley, Lydia O'Sullivan, Liam Grogan, et al.
Therapeutic Advances in Medical Oncology|February 1, 2018
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancersMalgorzata Milewska, Mattia Cremona, Clare Morgan, et al.
Blood|March 26, 2009
Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approachMatthias Niedermeier, Bryan T Hennessy, Zachary A Knight, et al.
Investigational New Drugs|April 23, 2020
Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd ALaura Breen, Patricia B Gaule, Alexandra Canonici, et al.
Cancer Cell|April 7, 2009
Rak functions as a tumor suppressor by regulating PTEN protein stability and functionEun-Kyoung Yim, Guang Peng, Hui Dai, et al.
The Journal of Clinical Investigation|June 10, 2010
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancerTodd W Miller, Bryan T Hennessy, Ana M González-Angulo, et al.
Pageof 25